Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark P Lythgoe

Showing results (11-20 of 65) with videos related to

Pageof 7
Sort By:
JAMA Network Open|June 25, 2021
Comparison of COVID-19 Vaccine Approvals at the US Food and Drug Administration, European Medicines Agency, and Health CanadaMark P Lythgoe, Paul Middleton
BMJ (Clinical Research Ed.)|August 31, 2023
Another setback for cancer research in the UKMark P Lythgoe, Richard Sullivan
The Lancet. Microbe|August 12, 2022
Could the UK's fixed-fee subscription improve access to antimicrobials and other essential medicines in low-income and middle-income countries?Mark P Lythgoe, Richard Sullivan
The Lancet. Oncology|April 3, 2025
Sexual health and reproductive toxicity from cancer therapiesDavid J Benjamin, Mark P Lythgoe
The Lancet. Oncology|March 1, 2023
Modernising the US FDA's Accelerated Approval pathwayDavid J Benjamin, Mark P Lythgoe
Nature Reviews. Clinical Oncology|May 31, 2023
The FDA's latest draft guidance on accelerated approvals - one step forward, two steps back?David J Benjamin, Mark P Lythgoe
Clinical Oncology (Royal College of Radiologists (Great Britain))|September 21, 2024
From Comfort to Cure: Re-Emphasizing Supportive and Palliative Care in OncologyDavid J Benjamin, Mark P Lythgoe
Journal of Immunology Research|September 18, 2015
Application of "Systems Vaccinology" to Evaluate Inflammation and Reactogenicity of Adjuvanted Preventative VaccinesDavid J M Lewis, Mark P Lythgoe
The Lancet. Oncology|September 1, 2023
UK oncology approvals in 2022: global regulatory collaboration and new regulatory pathways deliver new anti-cancer therapiesMark P Lythgoe, Richard Sullivan, Sarah Blagden
BMJ (Clinical Research Ed.)|March 23, 2022
High US drug prices have global implicationsKristina Jenei, Vinay Prasad, Mark P Lythgoe
Pageof 7

Showing results (11-20 of 65) with videos related to

Sort By:
Pageof 7
JAMA Network Open|June 25, 2021
Comparison of COVID-19 Vaccine Approvals at the US Food and Drug Administration, European Medicines Agency, and Health CanadaMark P Lythgoe, Paul Middleton
BMJ (Clinical Research Ed.)|August 31, 2023
Another setback for cancer research in the UKMark P Lythgoe, Richard Sullivan
The Lancet. Microbe|August 12, 2022
Could the UK's fixed-fee subscription improve access to antimicrobials and other essential medicines in low-income and middle-income countries?Mark P Lythgoe, Richard Sullivan
The Lancet. Oncology|April 3, 2025
Sexual health and reproductive toxicity from cancer therapiesDavid J Benjamin, Mark P Lythgoe
The Lancet. Oncology|March 1, 2023
Modernising the US FDA's Accelerated Approval pathwayDavid J Benjamin, Mark P Lythgoe
Nature Reviews. Clinical Oncology|May 31, 2023
The FDA's latest draft guidance on accelerated approvals - one step forward, two steps back?David J Benjamin, Mark P Lythgoe
Clinical Oncology (Royal College of Radiologists (Great Britain))|September 21, 2024
From Comfort to Cure: Re-Emphasizing Supportive and Palliative Care in OncologyDavid J Benjamin, Mark P Lythgoe
Journal of Immunology Research|September 18, 2015
Application of "Systems Vaccinology" to Evaluate Inflammation and Reactogenicity of Adjuvanted Preventative VaccinesDavid J M Lewis, Mark P Lythgoe
The Lancet. Oncology|September 1, 2023
UK oncology approvals in 2022: global regulatory collaboration and new regulatory pathways deliver new anti-cancer therapiesMark P Lythgoe, Richard Sullivan, Sarah Blagden
BMJ (Clinical Research Ed.)|March 23, 2022
High US drug prices have global implicationsKristina Jenei, Vinay Prasad, Mark P Lythgoe
Pageof 7